Company profile: Accelerate Diagnostics
1.1 - Company Overview
Company description
- Provider of in vitro diagnostic solutions for drug-resistant organisms and hospital-acquired infections, offering the Accelerate Pheno System for rapid ID and AST of bloodstream infections from positive blood cultures; the Accelerate Arc System for automated ID directly from positive blood cultures; the Accelerate PhenoTest BC Kit used with the Pheno system for fast ID and susceptibility results; and Gel Electrofiltration for sample cleanup.
Products and services
- Accelerate Pheno™ System: A diagnostic platform delivering rapid identification and antimicrobial susceptibility testing for bloodstream infections, direct-from-positive blood cultures, enabling timely, actionable results
- Accelerate PhenoTest® BC Kit: A kit used with the Accelerate Pheno system delivering fast identification and susceptibility results from positive blood cultures, accelerating decision-making for bloodstream infection treatment
- Accelerate Arc™ System: An automated system performing microbial identification directly from positive blood culture samples, designed to work with Bruker’s MALDI
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Accelerate Diagnostics
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent BioSolutions company profile →
Targanta Therapeutics
HQ: United States
Website
- Description: Provider of innovative antibiotics and antibacterial therapies for serious infections treated or acquired in hospitals and other institutional settings, including oritavancin, an intravenous bactericidal agent for Gram-positive infections with Phase III trials for complicated skin and skin structure infections; antibacterial pro-drugs for osteomyelitis; and a drug discovery platform that mimics strategies devised by bacterial viruses to target druggable bacterial mechanisms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Targanta Therapeutics company profile →
Sherlock Biosciences
HQ: United States
Website
- Description: Provider of engineering biology-based molecular diagnostics leveraging CRISPR and synthetic biology, including SHERLOCK for DNA/RNA detection and INSPECTR for instrument-free ambient tests, plus an FDA-authorized CRISPR SARS-CoV-2 kit. Offers global health partnerships to develop and distribute affordable infectious disease diagnostics and an internship & co-op program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sherlock Biosciences company profile →
Rebiotix
HQ: United States
Website
- Description: Provider of microbiome-based therapeutics targeting GI diseases, including FDA-approved REBYOTA for prevention of recurrence of Clostridioides difficile infection in adults; RBX2660, a live biotherapeutic in development for recurrent C. difficile; RBX7455, a non-frozen capsule in feasibility studies; and a Stool Donor Program supporting development of microbiome-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rebiotix company profile →
Rational Vaccines
HQ: United States
Website
- Description: Provider of pre-clinical live-attenuated herpes simplex virus vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rational Vaccines company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Accelerate Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Accelerate Diagnostics
2.2 - Growth funds investing in similar companies to Accelerate Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Accelerate Diagnostics
4.2 - Public trading comparable groups for Accelerate Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →